Skip to Main Content

Advertisement

Issue Archive

BLOOD COMMENTARIES

The investigators report on the promising activity of a phase 1b trial of the targeted therapy triplet rituximab, ibrutinib, and lenalidomide in patients with relapsed non–germinal center diffuse large B-cell lymphoma (DLBCL).

PLENARY PAPER

This study furnishes evidence that both confirms and refutes a long-standing maxim that a one-unit transfusion of red blood cells should yield a posttransfusion hemoglobin increment of 1 g/dL.

REVIEW ARTICLE

The authors review the latest knowledge of amino acid metabolism in hematologic malignancies and the clinical relevance and potential of amino acid therapeutic targeting.

CLINICAL TRIALS AND OBSERVATIONS

The investigators report on the promising activity of a phase 1b trial of the targeted therapy triplet rituximab, ibrutinib, and lenalidomide in patients with relapsed non–germinal center diffuse large B-cell lymphoma (DLBCL).

This study shows that the increased occurrence of stroke in thrombotic thrombocytopenic purpura (TTP) during remission is associated with low ADAMTS13 values.

HEMATOPOIESIS AND STEM CELLS

IMMUNOBIOLOGY AND IMMUNOTHERAPY

By comparing fetal and adult B-lymphopoiesis, the authors identify a prepro–B-cell subset in humans that marks the origin of B-cell lineage commitment in utero.

LYMPHOID NEOPLASIA

This paper reports that aggressive antibiotic treatment inhibits disease activity and lymphocyte proliferation in cutaneous T-cell lymphoma (CTCL). The study offers important evidence for a link between bacterial infection, activation of the immune system, and CTCL progression.

THROMBOSIS AND HEMOSTASIS

This study in mice suggests a synergistic role of ADAMTS13 deficiency and complement “hyperactivatability” in the pathogenesis of thrombotic microangiopathy.

LETTER TO BLOOD

BLOOD WORK

ERRATA

Close Modal
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close Modal
Close Modal

Advertisement